Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19

NCT04501783 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Favipiravir
DRUG: Standard of care (SOC)
DRUG: standard concomitant therapy

Sponsor

R-Pharm